{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:45:19Z","timestamp":1792799119428,"version":"4.5.0"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T00:00:00Z","timestamp":1503532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0183845","type":"journal-article","created":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T17:49:34Z","timestamp":1503596974000},"page":"e0183845","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy"],"prefix":"10.1371","volume":"12","author":[{"given":"Leonidas","family":"Apostolidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Weiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Heckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Godel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Heiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bendszus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"B\u00e4umer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,8,24]]},"reference":[{"issue":"8","key":"ref1","first-page":"711","article-title":"Adjuvant chemotherapy with oxaliplatin, in combination with fluorouracil plus leucovorin prolongs disease-free survival, but causes more adverse events in people with stage II or III colon cancer Abstracted from: Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter international study of oxaliplatin\/5-fluorouracil\/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343\u201351","volume":"30","year":"2004","journal-title":"Cancer treatment reviews"},{"issue":"16","key":"ref2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"A de Gramont","year":"2000","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"9","key":"ref3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","article-title":"Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"26","author":"SE Al-Batran","year":"2008","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"19","key":"ref4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"T Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"ref5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1470-2045(07)70281-4","article-title":"Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis","volume":"8","author":"V Golfinopoulos","year":"2007","journal-title":"The Lancet Oncology"},{"issue":"4","key":"ref6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"AA Argyriou","year":"2008","journal-title":"Cancer treatment reviews"},{"issue":"Suppl 1","key":"ref7","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3816\/CCC.2005.s.006","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"A Grothey","year":"2005","journal-title":"Clinical colorectal cancer"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update","volume":"82","author":"AA Argyriou","year":"2012","journal-title":"Critical reviews in oncology\/hematology"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000094376","article-title":"Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up","volume":"56","author":"A Pietrangeli","year":"2006","journal-title":"Eur Neurol"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2010-0248","article-title":"Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility","volume":"16","author":"SB Park","year":"2011","journal-title":"The oncologist"},{"issue":"2","key":"ref11","first-page":"342","article-title":"Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model","volume":"46","author":"J Holmes","year":"1998","journal-title":"Toxicological sciences: an official journal of the Society of Toxicology"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1002\/ana.24524","article-title":"Magnetic resonance neurography detects diabetic neuropathy early and with Proximal Predominance","volume":"78","author":"M Pham","year":"2015","journal-title":"Ann Neurol"},{"key":"ref13","article-title":"Posterior interosseous neuropathy: Supinator syndrome vs fascicular radial neuropathy","author":"P Baumer","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1148\/radiol.11102357","article-title":"Ulnar Neuropathy at the Elbow: MR Neurography\u2014Nerve T2 Signal Increase and Caliber","volume":"260","author":"P Baumer","year":"2011","journal-title":"Radiology"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"e0130833","DOI":"10.1371\/journal.pone.0130833","article-title":"Peripheral Nerve Diffusion Tensor Imaging: Assessment of Axon and Myelin Sheath Integrity","volume":"10","author":"A Heckel","year":"2015","journal-title":"PLoS One"},{"issue":"21","key":"ref16","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jnci\/86.21.1608","article-title":"Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial","volume":"86","author":"FA Levi","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1023\/A:1008344507482","article-title":"Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy","volume":"9","author":"TJ Postma","year":"1998","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mus.21661","article-title":"Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial","volume":"42","author":"PJ Dyck","year":"2010","journal-title":"Muscle Nerve"},{"issue":"Pt 10","key":"ref19","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1093\/brain\/awp219","article-title":"Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy","volume":"132","author":"SB Park","year":"2009","journal-title":"Brain"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/jnnp-2013-305334","article-title":"Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients","volume":"85","author":"R Velasco","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1212\/WNL.0b013e31822cfc59","article-title":"Longitudinal assessment of oxaliplatin-induced neuropathy","volume":"77","author":"AZ Burakgazi","year":"2011","journal-title":"Neurology"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1200\/JCO.1992.10.5.795","article-title":"Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity","volume":"10","author":"RW Gregg","year":"1992","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-2990.1999.00160.x","article-title":"Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study","volume":"25","author":"A Krarup-Hansen","year":"1999","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"ref24","first-page":"151","article-title":"Effects of repeated administration of low doses of cisplatin on the rat nervous system","volume":"13","author":"G Cavaletti","year":"1991","journal-title":"International journal of tissue reactions"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF00227662","article-title":"Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats","volume":"84","author":"G Cavaletti","year":"1992","journal-title":"Acta Neuropathol"},{"issue":"18","key":"ref26","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/S0959-8049(01)00300-8","article-title":"Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat","volume":"37","author":"G Cavaletti","year":"2001","journal-title":"European journal of cancer"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00280-004-0953-4","article-title":"Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss","volume":"56","author":"SM Jamieson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref28","first-page":"132837","article-title":"Peripheral Neuropathy: Detection with Diffusion-Tensor Imaging","author":"P Baumer","year":"2014","journal-title":"Radiology"},{"issue":"10","key":"ref29","first-page":"2098","article-title":"Morphologic analysis of normal human lumbar dorsal root ganglion by 3D MR imaging","volume":"27","author":"J Shen","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.14444\/2003","article-title":"Lumbar dorsal root Ganglia location: an anatomic and MRI assessment","volume":"9","author":"MP Silverstein","year":"2015","journal-title":"International journal of spine surgery"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MD.0000000000000024","article-title":"Use of a novel high-resolution magnetic resonance neurography protocol to detect abnormal dorsal root Ganglia in Sjogren patients with neuropathic pain: case series of 10 patients and review of the literature","volume":"93","author":"J Birnbaum","year":"2014","journal-title":"Medicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1289\/ehp.7826107","article-title":"Vascular permeability and neurotoxicity","volume":"26","author":"JM Jacobs","year":"1978","journal-title":"Environmental health perspectives"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1744-8069-4-10","article-title":"Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies","volume":"4","author":"JM Jimenez-Andrade","year":"2008","journal-title":"Molecular pain"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuroimage.2016.07.030","article-title":"Human dorsal-root-ganglion perfusion measured in-vivo by MRI","volume":"141","author":"T Godel","year":"2016","journal-title":"Neuroimage"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1172\/JCI68730","article-title":"Treatment of oxaliplatin-induced peripheral neuropathy by intravenous mangafodipir","volume":"124","author":"R Coriat","year":"2014","journal-title":"The Journal of clinical investigation"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1634\/theoncologist.2014-0044","article-title":"Platinum-induced neurotoxicity and preventive strategies: past, present, and future","volume":"20","author":"A Avan","year":"2015","journal-title":"The oncologist"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20","volume":"41","author":"TJ Postma","year":"2005","journal-title":"European journal of cancer"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin","volume":"25","author":"P Alberti","year":"2014","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology \/ ESMO"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0183845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T16:31:29Z","timestamp":1540225889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0183845"}},"subtitle":[],"editor":[{"given":"Rudolf","family":"Kirchmair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,24]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0183845","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,24]]}}}